Cargando…

Number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the Netherlands, 1989–2019

BACKGROUND: Loss of life expectancy (LOLE) may provide more intuitive information on the impact of cancer than relative survival over a fixed time horizon (e.g., 5-year relative survival). We aimed to assess the evolution of the LOLE using a nationwide, population-based cohort including patients dia...

Descripción completa

Detalles Bibliográficos
Autores principales: Maas, Carolien C.H.M., van Klaveren, David, Visser, Otto, Merkx, Matthias A.W., Lingsma, Hester F., Lemmens, Valery E.P.P., Dinmohamed, Avinash G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196760/
https://www.ncbi.nlm.nih.gov/pubmed/37214634
http://dx.doi.org/10.1016/j.eclinm.2023.101994
_version_ 1785044413696704512
author Maas, Carolien C.H.M.
van Klaveren, David
Visser, Otto
Merkx, Matthias A.W.
Lingsma, Hester F.
Lemmens, Valery E.P.P.
Dinmohamed, Avinash G.
author_facet Maas, Carolien C.H.M.
van Klaveren, David
Visser, Otto
Merkx, Matthias A.W.
Lingsma, Hester F.
Lemmens, Valery E.P.P.
Dinmohamed, Avinash G.
author_sort Maas, Carolien C.H.M.
collection PubMed
description BACKGROUND: Loss of life expectancy (LOLE) may provide more intuitive information on the impact of cancer than relative survival over a fixed time horizon (e.g., 5-year relative survival). We aimed to assess the evolution of the LOLE using a nationwide, population-based cohort including patients diagnosed with one of 17 most frequent solid malignancies. METHODS: From the Netherlands Cancer Registry, we selected adult patients diagnosed with one of the 17 most frequent solid malignancies in the Netherlands during 1989–2019, with survival follow-up until 2022. We used flexible parametric survival models to estimate the LOLE at diagnosis and the LOLE after surviving several years post-diagnosis (conditional LOLE; CLOLE) by cancer type, calendar year, age, sex, and disease stage. FINDINGS: For all cancers combined, the LOLE consistently decreased from 1989 to 2019. This decrease was most pronounced for males with prostate cancer (e.g., from 6.9 [95% confidence interval [CI], 6.7–7.1] to 2.7 [95% CI, 2.5–3.0] for 65-year-olds) and females with breast cancer (e.g., from 6.6 [95% CI, 6.4–6.7] to 1.9 [95% CI, 1.8–2.0] for 65-year-olds). The LOLE among patients with cancers of the head and neck or the central nervous system remained constant over time. Overall, the CLOLE showed that the life years lost among patients with cancer decreased with each additional year survived post-diagnosis. For example, the LOLE at diagnosis for 65-year-old females diagnosed with breast cancer in 2019 was 1.9 [95% CI, 1.8–2.0] compared with 1.7 [95% CI, 1.6–1.8], 1.0 [95% CI, 0.9–1.1], and 0.5 [95% CI, 0.5–0.6] when surviving one, five, and ten years post-diagnosis, respectively. Estimates for other combinations of patient and tumour characteristics are available in a publicly available web-based application. INTERPRETATION: Our findings suggested that the evolution of LOLE substantially varies across cancer type, age, and disease stage. LOLE estimates help patients better understand the impact of their specific cancer diagnosis on their life expectancy. FUNDING: None.
format Online
Article
Text
id pubmed-10196760
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101967602023-05-20 Number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the Netherlands, 1989–2019 Maas, Carolien C.H.M. van Klaveren, David Visser, Otto Merkx, Matthias A.W. Lingsma, Hester F. Lemmens, Valery E.P.P. Dinmohamed, Avinash G. eClinicalMedicine Articles BACKGROUND: Loss of life expectancy (LOLE) may provide more intuitive information on the impact of cancer than relative survival over a fixed time horizon (e.g., 5-year relative survival). We aimed to assess the evolution of the LOLE using a nationwide, population-based cohort including patients diagnosed with one of 17 most frequent solid malignancies. METHODS: From the Netherlands Cancer Registry, we selected adult patients diagnosed with one of the 17 most frequent solid malignancies in the Netherlands during 1989–2019, with survival follow-up until 2022. We used flexible parametric survival models to estimate the LOLE at diagnosis and the LOLE after surviving several years post-diagnosis (conditional LOLE; CLOLE) by cancer type, calendar year, age, sex, and disease stage. FINDINGS: For all cancers combined, the LOLE consistently decreased from 1989 to 2019. This decrease was most pronounced for males with prostate cancer (e.g., from 6.9 [95% confidence interval [CI], 6.7–7.1] to 2.7 [95% CI, 2.5–3.0] for 65-year-olds) and females with breast cancer (e.g., from 6.6 [95% CI, 6.4–6.7] to 1.9 [95% CI, 1.8–2.0] for 65-year-olds). The LOLE among patients with cancers of the head and neck or the central nervous system remained constant over time. Overall, the CLOLE showed that the life years lost among patients with cancer decreased with each additional year survived post-diagnosis. For example, the LOLE at diagnosis for 65-year-old females diagnosed with breast cancer in 2019 was 1.9 [95% CI, 1.8–2.0] compared with 1.7 [95% CI, 1.6–1.8], 1.0 [95% CI, 0.9–1.1], and 0.5 [95% CI, 0.5–0.6] when surviving one, five, and ten years post-diagnosis, respectively. Estimates for other combinations of patient and tumour characteristics are available in a publicly available web-based application. INTERPRETATION: Our findings suggested that the evolution of LOLE substantially varies across cancer type, age, and disease stage. LOLE estimates help patients better understand the impact of their specific cancer diagnosis on their life expectancy. FUNDING: None. Elsevier 2023-05-11 /pmc/articles/PMC10196760/ /pubmed/37214634 http://dx.doi.org/10.1016/j.eclinm.2023.101994 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Maas, Carolien C.H.M.
van Klaveren, David
Visser, Otto
Merkx, Matthias A.W.
Lingsma, Hester F.
Lemmens, Valery E.P.P.
Dinmohamed, Avinash G.
Number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the Netherlands, 1989–2019
title Number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the Netherlands, 1989–2019
title_full Number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the Netherlands, 1989–2019
title_fullStr Number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the Netherlands, 1989–2019
title_full_unstemmed Number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the Netherlands, 1989–2019
title_short Number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the Netherlands, 1989–2019
title_sort number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the netherlands, 1989–2019
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196760/
https://www.ncbi.nlm.nih.gov/pubmed/37214634
http://dx.doi.org/10.1016/j.eclinm.2023.101994
work_keys_str_mv AT maascarolienchm numberoflifeyearslostatthetimeofdiagnosisandseveralyearspostdiagnosisinpatientswithsolidmalignanciesapopulationbasedstudyinthenetherlands19892019
AT vanklaverendavid numberoflifeyearslostatthetimeofdiagnosisandseveralyearspostdiagnosisinpatientswithsolidmalignanciesapopulationbasedstudyinthenetherlands19892019
AT visserotto numberoflifeyearslostatthetimeofdiagnosisandseveralyearspostdiagnosisinpatientswithsolidmalignanciesapopulationbasedstudyinthenetherlands19892019
AT merkxmatthiasaw numberoflifeyearslostatthetimeofdiagnosisandseveralyearspostdiagnosisinpatientswithsolidmalignanciesapopulationbasedstudyinthenetherlands19892019
AT lingsmahesterf numberoflifeyearslostatthetimeofdiagnosisandseveralyearspostdiagnosisinpatientswithsolidmalignanciesapopulationbasedstudyinthenetherlands19892019
AT lemmensvaleryepp numberoflifeyearslostatthetimeofdiagnosisandseveralyearspostdiagnosisinpatientswithsolidmalignanciesapopulationbasedstudyinthenetherlands19892019
AT dinmohamedavinashg numberoflifeyearslostatthetimeofdiagnosisandseveralyearspostdiagnosisinpatientswithsolidmalignanciesapopulationbasedstudyinthenetherlands19892019